NasdaqGS - Nasdaq Real Time Price • USD
Ascendis Pharma A/S (ASND)
As of 1:36 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 2 | 2 |
| Avg. Estimate | 0 | 0 | -0.05 | -0.05 |
| Low Estimate | 0 | 0 | -0.1 | -0.1 |
| High Estimate | 0 | 0 | -0.01 | -0.01 |
| Year Ago EPS | -- | -- | -0.08 | -0.05 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 12/31/2022 | |||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | 0 |
| EPS Actual | -- | -- | -- | -0.05 |
| Difference | -- | -- | -- | -0.05 |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | -0.05 | -0.05 |
| 7 Days Ago | 0 | 0 | -0.06 | -0.06 |
| 30 Days Ago | 0 | 0 | -0.02 | 0.13 |
| 60 Days Ago | 0 | 0 | -0.02 | 0.13 |
| 90 Days Ago | 0 | 0 | -0.02 | 0.13 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ASND | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 1.50% |
| Next Qtr. | -- | -- | -- | 12.10% |
| Current Year | 37.50% | -- | -- | 4.40% |
| Next Year | 0.00% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -- | -- | -- | 10.97% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Morgan Stanley: Equal-Weight to Equal-Weight | 4/22/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 4/2/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 3/15/2024 |
| Maintains | Citigroup: Buy to Buy | 2/8/2024 |
Related Tickers
PCVX Vaxcyte, Inc.
60.64
+0.97%
ARGX argenx SE
375.31
+1.82%
BPMC Blueprint Medicines Corporation
94.50
+4.15%
IMVT Immunovant, Inc.
27.55
-0.72%
KRYS Krystal Biotech, Inc.
156.72
+0.67%
LEGN Legend Biotech Corporation
44.81
+0.88%
GMAB Genmab A/S
28.08
+2.26%
VRNA Verona Pharma plc
15.56
+1.63%
RARE Ultragenyx Pharmaceutical Inc.
44.45
+1.37%
SWTX SpringWorks Therapeutics, Inc.
45.50
+2.94%